Epstein Secrets

ynthetic Cannabinoids Screen (2019 Scope), Blood - Femoral Blood -Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry QTRAP (LC-MS/MS QTRAP) for. Compound 4-cyano-CUMYL-BINACA 0.10 ng/mL AMB-FUBINACA 1.0 ng/mL 4-fluoro-MDMB-BINACA 0.10 ng/mL CUMYL-THPINACA 0.10 ng/mL 5

orksheet the EMS ACR, and the ED Notes. These were received except the ACR. An email was sent to Evidence Request with cc's to Evidence Pickups and OCME Tour Commanders requesting that the ACR be obtained. The undersigned was accompanied by Deputy Director of Forensic Investi•ations and O erations, for a MLI scen

ynthetic Cannabinotds Screen (2019 Scope), Blood - Femoral Blood -Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry QTRAP (LC-MS/MS QTRAP) for aaranstuad Ret Limit COOMBS' Rot—Limit 4-cyano-CUMYL-BINACA 0.10 ng/mL AMB-FUBINACA 1.0 ng/mL 4-fluoro-MDMB-BINACA 0.10 ng/m

orksheet the EMS ACR, and the ED Notes. These were received except the ACR. An email was sent to Evidence Request with cc's to Evidence Pickups and OCME Tour Commanders requesting that the ACR be obtained. The undersigned was accompanied by Nicholas Schultz, Deputy Director of Forensic Investigations and Operation

ynthetic Cannabinoids Screen (2019 Scope), Blood - Femoral Blood -Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry QTRAP (LC-MS/MS QTRAP) for Compound Rid I iat C.00.12011XL Rot Limit 4-cyano-CUMYL-BINACA 0.10 ng/mL AMB-FUBINACA 1.0 ng/mL 4-fluoro-MDMB-BINACA 0.10 n

ical Summary E IR IP iand the ED Notes. These were received except the ACR. An email was sent to Evidence Request with cc's to Evidence Pickups and OCME Tour Commanders requesting that the ACR be obtained. The undersigned was accompanied by Deputy Director of Forensic Investi ations ancaberations, for a MLI scene